International Regulome Consortium continues to grow: Ottawa-led stem cell research group partners with Invitrogen

June 18, 2008

The International Regulome Consortium (IRC) announced today it has signed a non-binding letter of intent with Invitrogen Corporation to develop tools for stem cell research that will aid in the development of new therapies for some of the world’s most debilitating diseases.

Invitrogen will contribute services and technology to help IRC researchers in their goal of mapping the genetic circuit board that regulates how stem cells give rise to specialized cells such as neurons. IRC is a third generation genome project, involving 58 researchers from 34 institutions in 12 countries.

The IRC is led by Dr. Michael Rudnicki, Director and Senior Scientist at the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute at The Ottawa Hospital. Dr. Rudnicki is also a Professor in the Faculty of Medicine at the University of Ottawa and Scientific Director of the Stem Cell Network.

International Regulome Consortium press release
International Regulome Consortium website
Dr. Michael Rudnicki’s OHRI Scientist Profile